Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.50 |
| ▸ | GRM5 | P41594 | 4/20 | 0.49 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.48 |
| ▸ | GRM1 | Q13255 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | DTYMK | P23919 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21748717 | 0.82 | POLB (0.45) | GPR119GRM5USP30GRM1POLB | |
| SCHEMBL1617581 | 0.82 | RORC (0.48) | GPR119USP30MAPK1JAK2JAK1 | |
| SCHEMBL28491036 | 0.81 | GPR119 (0.56) | GPR119GRM5USP30GRM1POLB | |
| SCHEMBL18115645 | 0.80 | GPR119 (0.59) | GPR119USP30 | |
| SCHEMBL5161957 | 0.80 | GPR119 (0.43) | GPR119GRM5USP30GRM1MAPK1 | |
| SCHEMBL30783165 | 0.80 | GPR119 (0.43) | GPR119GRM5USP30GRM1MAPK1 | |
| SCHEMBL27211314 | 0.80 | GRM1 (0.44) | GPR119GRM5USP30GRM1MAPK1 | |
| SCHEMBL31228209 | 0.79 | GPR119 (0.54) | GPR119GRM5USP30GRM1POLB | |
| SCHEMBL2998444 | 0.79 | GPR119 (0.54) | GPR119GRM5USP30GRM1POLB | |
| SCHEMBL15359029 | 0.79 | GPR119 (0.47) | GPR119GRM5USP30GRM1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1748984-A1 | PIPERIDINE DERIVATIVES AS NK1 AND NK3 ANTAGONISTS | Pfizer Products Inc. (US) | 2007-02-07 | — | — | EP | disclosed |
| WO-2005110987-A1 | PIPERIDINE DERIVATIVES AS NK1 AND NK3 ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2005-11-24 | — | — | WO | disclosed |
| US-20050256164-A1 | NK1 and NK3 antagonists | PFIZER INC | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256164-A1 | NK1 and NK3 antagonists | TAC3, TACR1, TACR2 | GPR119 522/4885GRM5 488/4885USP30 3958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.